Polaris Genomics
Polaris Genomics is mapping molecular biomarkers to chart a new course for objective mental health diagnostics and novel therapeutics. Polaris Genomics identifies genomic biomarkers to support the development of psychiatric drugs and clinical tools. The company's genomics-based ADAPT Platform™ curates information on biologically-relevant gene network pathways indicated in neuropsychiatric conditions — including anxiety, depression, alcohol/substance use disorder, ADHD, PTSD, and TBI (ADAPT). The ADAPT Platform™ comprises: 1. targeted neuropsychiatric gene panel, which contains 1000+ transcriptomic biomarkers related to known system pathways in neuropsychiatric conditions; 2. deep analytics (AI/ML) engine; and 3. expanding data lake and sample repository. ADAPT has identified transcriptomic biomarkers for PTSD, resulting in the first-of-its-kind clinical blood test for PTSD screening, Polaris' PTS-ID™.
Domain
polarisgenomics.com
Country
United StatesIndustry
BioinformaticsEmployees
11-50
Last Funding
$0.3M
Founded
2016
Tech Stack (16 technologies)
Frequently Asked Questions
What technologies does Polaris Genomics use?+
Polaris Genomics uses 16 technologies including Divi, Google Analytics, Google Tag Manager.
What industry is Polaris Genomics in?+
Polaris Genomics operates in the Bioinformatics industry.
Where is Polaris Genomics based?+
Polaris Genomics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026